A Novel Fully Human Antitumour ImmunoRNase Targeting ErbB2-positive Tumours

Overview

Journal Br J Cancer

Specialty Oncology

Date 2011 May 12

PMID 21559015

Citations 16

Authors

M Borriello

P Laccetti

G Terrazzano

G DAlessio

C De Lorenzo

Affiliations

Soon will be listed here.

Abstract

Background: ErbB2 is an attractive target for immunotherapy, as it is a tyrosine kinase receptor overexpressed on tumour cells of different origin, with a key role in the development of malignancy. Trastuzumab, the only humanised anti-ErbB2 antibody currently used in breast cancer with success, can engender cardiotoxicity and a high fraction of patients is resistant to Trastuzumab treatment.

Methods: A novel human immunoRNase, called anti-ErbB2 human compact antibody-RNase (Erb-hcAb-RNase), made up of the compact anti-ErbB2 antibody Erbicin-human-compact Antibody (Erb-hcAb) and human pancreatic RNase (HP-RNase), has been designed, expressed in mammalian cell cultures and purified. The immunoRNase was then characterised as an enzymatic protein, and tested for its biological actions in vitro and in vivo on ErbB2-positive tumour cells.

Results: Erb-hcAb-RNase retains the enzymatic activity of HP-RNase and specifically binds to ErbB2-positive cells with an affinity comparable with that of the parental Erb-hcAb. Moreover, this novel immunoRNase is endowed with an effective and selective antiproliferative action for ErbB2-positive tumour cells both in vitro and in vivo. Its antitumour activity is more potent than that of the parental Erb-hcAb as the novel immunoconjugate has acquired RNase-based cytotoxicity in addition to the inhibitory growth effects, antibody-dependent and complement-dependent cytotoxicity of Erb-hcAb.

Conclusion: Erb-hcAb-RNase could be a promising candidate for the immunotherapy of ErbB2-positive tumours.

Citing Articles

Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics.

Passariello M, Manna L, Rapuano Lembo R, Yoshioka A, Inoue T, Kajiwara K Cell Death Discov. 2025; 11(1):58.

PMID: 39929828 PMC: 11811032. DOI: 10.1038/s41420-025-02329-8.

Macromolecular Cargo Encapsulation via In Vitro Assembly of Two-Component Protein Nanoparticles.

Herpoldt K, Lopez C, Sappington I, Pham M, Srinivasan S, Netland J Adv Healthc Mater. 2024; 13(11):e2303910.

PMID: 38180445 PMC: 11468305. DOI: 10.1002/adhm.202303910.

A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies.

Manna L, Rapuano Lembo R, Yoshioka A, Nakamura K, Passariello M, De Lorenzo C Cancers (Basel). 2023; 15(22).

PMID: 38001604 PMC: 10670465. DOI: 10.3390/cancers15225345.

Design, optimization, production and activity testing of recombinant immunotoxins expressed in plants and plant cells for the treatment of monocytic leukemia.

Knodler M, Frank K, Kerpen L, Buyel J Bioengineered. 2023; 14(1):2244235.

PMID: 37598369 PMC: 10444015. DOI: 10.1080/21655979.2023.2244235.

A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab.

Passariello M, Ferrucci V, Sasso E, Manna L, Rapuano Lembo R, Pascarella S Int J Mol Sci. 2022; 23(10).

PMID: 35628365 PMC: 9146290. DOI: 10.3390/ijms23105556.

References

Carter P . Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2002; 1(2):118-29. DOI: 10.1038/35101072. View

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer. 1998; 77(1):1-10. PMC: 2151254. DOI: 10.1038/bjc.1998.1. View

Stebbing J, Copson E, OReilly S . Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat Rev. 2000; 26(4):287-90. DOI: 10.1053/ctrv.2000.0182. View

Menzel C, Schirrmann T, Konthur Z, Jostock T, Dubel S . Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood. 2008; 111(7):3830-7. DOI: 10.1182/blood-2007-04-082768. View

Schindler J, Sausville E, Messmann R, UHR J, Vitetta E . The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin Cancer Res. 2001; 7(2):255-8. View

Adams G, Weiner L . Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005; 23(9):1147-57. DOI: 10.1038/nbt1137. View

Venkiteshwaran A . Tocilizumab. MAbs. 2010; 1(5):432-8. PMC: 2759492. DOI: 10.4161/mabs.1.5.9497. View

De Lorenzo C, DAlessio G . Human anti-ErbB2 immunoagents--immunoRNases and compact antibodies. FEBS J. 2009; 276(6):1527-35. DOI: 10.1111/j.1742-4658.2009.06896.x. View

10.

Harris M . Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 2004; 5(5):292-302. DOI: 10.1016/S1470-2045(04)01467-6. View

11.

Rybak S, Newton D . Natural and engineered cytotoxic ribonucleases: therapeutic potential. Exp Cell Res. 1999; 253(2):325-35. DOI: 10.1006/excr.1999.4718. View

12.

Weiner L, ODwyer J, Kitson J, Comis R, Frankel A, Bauer R . Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res. 1989; 49(14):4062-7. View

13.

Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E . DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol. 2000; 165(9):5133-42. DOI: 10.4049/jimmunol.165.9.5133. View

14.

Li J, Zhu Z . Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin. 2010; 31(9):1198-207. PMC: 4002304. DOI: 10.1038/aps.2010.120. View

15.

Gelardi T, Damiano V, Rosa R, Bianco R, Cozzolino R, Tortora G . Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours. Br J Cancer. 2010; 102(3):513-9. PMC: 2822937. DOI: 10.1038/sj.bjc.6605499. View

16.

Reiter Y, Pastan I . Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol. 1999; 16(12):513-20. DOI: 10.1016/s0167-7799(98)01226-8. View

17.

De Lorenzo C, Palmer D, Piccoli R, Ritter M, DAlessio G . A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res. 2002; 8(6):1710-9. View

18.

Nahta R, Yu D, Hung M, Hortobagyi G, Esteva F . Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006; 3(5):269-80. DOI: 10.1038/ncponc0509. View

19.

Di Carlo E, Diodoro M, Boggio K, Modesti A, Modesti M, Nanni P . Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest. 1999; 79(10):1261-9. View

20.

De Lorenzo C, Tedesco A, Terrazzano G, Cozzolino R, Laccetti P, Piccoli R . A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. Br J Cancer. 2004; 91(6):1200-4. PMC: 2747711. DOI: 10.1038/sj.bjc.6602110. View